<DOC>
	<DOC>NCT00314184</DOC>
	<brief_summary>This is a multicenter, randomized, parallel-group, double-blind, placebo-controlled study to evaluate the efficacy and safety of quetiapine and lithium (comparator in the study) for up to 104 weeks of maintenance treatment in adult patients with Bipolar I Disorder. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.</brief_summary>
	<brief_title>Quetiapine Fumarate Bipolar Maintenance Monotherapy</brief_title>
	<detailed_description />
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Signed informed consent 18 years or older A diagnosis of Bipolar I Disorder Have a current manic, depressed or mixed episode Have had a manic, depressed or mixed episode during the last 26 weeks that was treated with quetiapine Female patients of childbearing potential must be using a reliable method of contraception Pregnancy Substance or alcohol dependence at enrollment Unstable thyroid function Unstable Diabetes Unstable or inadequately treated medical illness e.g., angina pectoris and hypertension Use of an experimental drug within 30 days of enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Bipolar I disorder.</keyword>
</DOC>